Press Release Details

DermTech Abstracts Selected to Present at Society of Investigative Dermatology Virtual Meeting

February 22, 2021 at 4:30 PM EST

LA JOLLA, Calif.--(BUSINESS WIRE)--Feb. 22, 2021-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that four of its abstracts were selected by the Society for Investigative Dermatology (“SID”) for presentation at the SID Virtual Meeting, taking place May 3-8, 2021. The SID is committed to the advancement of skin health and disease through education, advocacy and scholarly exchange of scientific information. In addition to virtual sessions, the abstracts will be published in a forthcoming supplemental issue of the Journal of Investigative Dermatology.

As part of the selection, DermTech Chief Scientific Officer Michael Howell, Ph.D. will present “Non‑Invasively Stratifying Atopic Dermatitis Patients Based on Inflammatory Genes” in one of the Mini‑Symposia, with a focus on patient-targeted research.

The following additional research abstracts from DermTech, which cover topics such as the genomics of non-melanoma skin cancer, UV induced DNA mutations, and long-term follow‑up data on DermTech’s melanoma test, the Pigmented Lesion Assay, or PLA, will be presented as ePoster presentations:

  • “Identification of Novel Gene Classifiers to Non-Invasively Diagnose Non-Melanoma Skin Cancer” by Christopher Adase, et al.
  • “A Non-Invasive Genomic Test for Early Assessment of UV Damage in Human Skin” by Prateek Tripathi, et al.
  • “Long-Term Outcome of Pigmented Lesions Clinically Suspicious for Melanoma Previously Tested with the Pigmented Lesion Assay (PLA): Results from the TRUST Study” by James Rock, et al.

“The Society of Investigative Dermatology virtual meeting brings together leaders in skin and disease biology as well as those advancing precision and personalized approaches to dermatology. DermTech is excited to present our innovative non-invasive platform and our precision approach to personalized dermatology,” said Michael Howell, Ph.D., chief scientific officer of DermTech.

For more information about the Society of Investigative Dermatology, please visit: For more information about DermTech, please visit:

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at:

Forward-Looking Statements:

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: DermTech’s plans to attend the SID virtual meeting, the performance, patient benefits, cost‑effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Sarah Dion

Crowe PR
Sarah Gallagher

Source: DermTech, Inc.